Myricx Bio raised $114m in Series A funding co-led by Abingworth and Novo Holdings, joined by insiders Brandon Capital and Sofinnova Partners.

Health services Pharma

United Kingdom

Australia

Denmark

France

Investments

01 July 2024

Share:

Myricx Bio (company)

United Kingdom

Health services Pharma

Total investments received (USD): 120.02m

Round value (USD): 114m

Round investors: Brandon Capital Partners Novo A/S Sofinnova Partners Abingworth

Company: Myricx Bio

Industry: Health services Pharma

Related deals

Verdiva Bio raised $410m in Series A funding co-led by Forbion and General Atlantic

Biotech Health services Manufacturing Pharma

United Kingdom

Netherlands

United States

Singapore

China

Investments 10 December 2024

F2G raised a $100m round co-led AMR Action Fund and ICG, joined by Novo, Advent Life, Sofinnova, Forbion, Blue Owl, Morningside, and Merifin Capital.

Biotech Health services Pharma

United Kingdom

United States

Netherlands

Denmark

France

Belgium

Investments 01 September 2024

Exscientia to merge operations with Recursion from the US in a $668m deal

Biotech Health services Pharma Software Services

United Kingdom

MA 02 August 2024

Beacon Therapeutics raised $170m in Series B funding led by Forbion, joined by TCGX, Advent Life Sciences, Syncona, Oxford Science Enterprises.

Health services Manufacturing Pharma

United Kingdom

Netherlands

United States

Investments 30 June 2024

Amber Tx in a $100m (£80m) in Series A led by NEA, joined by F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises and 8VC.

Biotech Health services Pharma

United Kingdom

United States

Investments 02 June 2024